11

Wanbury LimitedWanbury Limited

February 2006February 2006

Wanbury Limited

DisclaimerDisclaimer

This presentation is made purely for information. We have tried to give relevant information which we believe will help in understanding the Company. The viewers may use their own judgement and are advised to make their own calculations before deciding on any matter based on the information given herein. While every care is taken to verify the accuracy of the information given in this presentation, neither the Company nor its officials would in any way be liable for any action taken or not taken by the viewers or the users of this presentation or for any claims, losses etc. This is not a prospectus or document soliciting investment in the Company

33

OverviewOverview

Wanbury Limited

Our Vision …Our Vision …

To become a global pharmaceutical company To become a global pharmaceutical company with presence in Formulations and APIs ….with presence in Formulations and APIs ….

… … a market capitalisation in excess of Rs.1000 cr a market capitalisation in excess of Rs.1000 cr

…… ……by March 2009by March 2009

Wanbury Limited

Business ModelBusiness Model

BULK BULK BUSINESSBUSINESS

DOMESTIC DOMESTIC FORMULATIONS FORMULATIONS FORMULATIONSFORMULATIONS

OVERSEASOVERSEAS

Existing Existing

Export Focus Export Focus

3 Plants3 Plants

ExistingExisting

Focus on Domestic Focus on Domestic Ethical BrandsEthical Brands

New Product Intros.New Product Intros.

ExistingExisting

NoneNone

PlannedPlanned

ExpansionExpansion

Addl. plantAddl. plant

PlannedPlanned

Brand acquisitionsBrand acquisitions

Addition of division in Addition of division in medium termmedium term

Strategic Strategic AssociationsAssociations

PlannedPlanned

European European Generics Generics

66

Bulk BusinessBulk Business

Wanbury Limited

SnapshotSnapshot

World’s largest producer of Metformin World’s largest producer of Metformin

We sell to leading global generic players in regulated marketsWe sell to leading global generic players in regulated markets

Exporting to over 50 countriesExporting to over 50 countries

Over 14 products ... Of these over 8 products for US and EuropeOver 14 products ... Of these over 8 products for US and Europe

3 API facilities with 2 USFDA approved for multi product in Maharashtra 3 API facilities with 2 USFDA approved for multi product in Maharashtra and APand AP

Over 24 products within 18 months and foray in contract manufacturingOver 24 products within 18 months and foray in contract manufacturing

Aggressive pitch of DMF Filings through a strengthened Research Base. Aggressive pitch of DMF Filings through a strengthened Research Base. New R&D centre set up at Navi Mumbai for Process ResearchNew R&D centre set up at Navi Mumbai for Process Research

Wanbury Limited

Key CustomersKey Customers

Apotex, CanadaApotex, Canada Torr Pharma, USATorr Pharma, USA Mylan, USAMylan, USA Barr Laboratories, USABarr Laboratories, USA TEVA, IsraelTEVA, Israel Dexxon, IsraelDexxon, Israel Pliva, USAPliva, USA Remedica, CyprusRemedica, Cyprus Drageno Pharma, GermanyDrageno Pharma, Germany Moleculus MexicoMoleculus Mexico PfizerPfizer

Mega Pharma, Mexico Mega Pharma, Mexico Pure Pharma, EuropePure Pharma, Europe Salutos, GermanySalutos, Germany Wessex, UKWessex, UK Tabuk, Saudi ArabiaTabuk, Saudi Arabia Pharmire, Sourth KoreaPharmire, Sourth Korea Ranbaxy, IndiaRanbaxy, India Strides Arcolabs Strides Arcolabs Glenmark,India Glenmark,India Sun Pharma, IndiaSun Pharma, India Cadila PharmaceuticalsCadila Pharmaceuticals Alkem, India Alkem, India

Wanbury Limited

Product PortfolioProduct Portfolio MetforminMetformin SalsalateSalsalate IbuprofenIbuprofen GlucosamineGlucosamine Mefenamic AcidMefenamic Acid

MeloxicamMeloxicam FluvastatinFluvastatin Glybenclamide Glybenclamide GabapenteneGabapentene ClopidogrelClopidogrel

Existing Existing

Sertraline Sertraline Paroxetine HemihydrateParoxetine Hemihydrate CarvedilolCarvedilol DesloratidineDesloratidine Losartan PotassiumLosartan Potassium

Gabapentene Gabapentene Int.Int.

TramadolTramadol Amitryiptyline Amitryiptyline

PromethazinePromethazine

Introductions Introductions this yearthis year

Pipeline Pipeline for 2007for 2007

GliclazideGliclazide PantaprazolePantaprazole FluconazoleFluconazole HydrochlorthyzidHydrochlorthyzid

ee

…….a market size of over $ 2 Bn .a market size of over $ 2 Bn

Wanbury Limited

Product PipelineProduct Pipeline

DMFs in Process Lab Stage New ProductsScale up

Metformin HCl

Tramadol Hydrochloride (EDQM)

Tramadol Hydrochloride( US)

Promethazine Hydrochloride

Sertraline Hydrochloride

Amitriptyline Hydrochloride

Paroxetine Hydrochloride

Metformin HCl DC grade 90%

Metformin HCl DC grade 95%

Ibuprofen DC grade 90%

Glucosamine HCl

Ibuprofen

Mefenamic acid

Losartan Potassium Carvedilol

Clopidogrel Hydrogen

sulphate

Carvedilol

Diphenhydramine

Hydrochloride

Glucosamine Sulfate Kcl

Glucosamine Sulfate NaCl

DMFs Available

Ondansetron

Risperidone

Venlafaxine

Glimepiride

Pantaprazole

Methoxsalen

Irbesartan

Meloxicam

Fluvastatin

Glybenclamide

Gliclazide

Fluconazole

Venlafaxine

Wanbury Limited

Our Research StrategyOur Research Strategy

Process Research

PharmaResearch

NDDS

APIs for Regulated markets

/Emerging markets

and Contract manufacturing

Development of ANDAs and

finished dosages for regulated

markets

Development of novel platforms

for Specialty Generics and IPR

Time FrameTime Frame ActivityActivity ScientistsScientists OutlayOutlay ExpertiseExpertise

Existing Existing Existing set up Existing set up Formulations and R&D Formulations and R&D

researchresearch

1515 -- APIs for Regulated MarketsAPIs for Regulated Markets

By March ’05By March ’05 New centre for Process New centre for Process ResearchResearch

4545 Rs. 5crRs. 5cr DMFs and Contract DMFs and Contract Manufacturing Manufacturing

By Nov ‘06By Nov ‘06 New Centre for Research New Centre for Research 7070 Rs.15crRs.15cr Formulations Research + Formulations Research + NDDSNDDS

Wanbury Limited

Our Research StrategyOur Research Strategy

NDDS

Development of novel platformsfor Speciality Generics and IPR

Pharma ResearchDevelopment of ANDAs and

finished dosages for regulated markets

Process Research APIs for Regulated markets /Emerging markets

and Custom Synthesis

NCE

Wanbury Limited

Stage I- Process Research Stage I- Process Research CenterCenter Area of Focus

– Widening DMF pipeline for regulated markets (10 DMFs over 15 m)

– New Product introductions for emerging markets

– Intermediate manufacturing for innovators

– Development for Contract Manufacturing

– Widened coverage of therapeutic area

_ Custom synthesis Research Set-up

– Existing facilities to be strengthened and new Research Facility being set up in Navi Mumbai

– Team comprising 20 scientists with 4 PhDs in Organic Chemistry

– Well equipped analytical Lab comprising HPLCs, GCs, FTIR, UV Visible, Particle size analyser etc

– Team expandable to 60 scientists over 24 months

Wanbury Limited

Stage II Research CenterStage II Research Center

Area of Focus– Development of Formulations – Dossier preparations and ANDA filings for regulated markets– Development of platforms for Novel Drug Delivery for Speciality

Generics– Clinical Research Capabilities for carrying out bio equivalence

studies

Research Set-up– New facility for a closed loop research lab to be set up close to

Mumbai/Pune– Full service Analytical Lab with NMR, HPLCs, GCs,

FTIRs, ,XRD,DSC,GCMS,LCMS.– Lab Management Systems – Clinical Research capabilities starting with capabilities for bio

equivalence studies – Facilities for In vivo studies– Animal House for In vitro studies studies

Wanbury Limited

Contract ManufacturingContract Manufacturing

Wanbury is well positioned to emerge as an outsourcing partner of choice due to our quest for quality, desire for innovation, a highly efficient supply chain management and optimal utilization of capacities.

Wanbury is in an unique position to offer a single point of contract for R&D, process development and production. Availability of dedicated, adequately trained and highly qualified manpower in R&D , production and QA/RA.

Wanbury Limited

Custom SynthesisCustom Synthesis

Custom synthesisCustom synthesis

– Already carrying out synthesis for European Already carrying out synthesis for European customerscustomers

– Expanding team of scientific officers to procure Expanding team of scientific officers to procure businessbusiness

– New systems to be incorporated in the R&D to New systems to be incorporated in the R&D to strengthen IPR protection and facilitate businessstrengthen IPR protection and facilitate business

Wanbury Limited

Reaction CapabilitiesReaction Capabilities

In addition to general reactions we are specialised in the following In addition to general reactions we are specialised in the following AzidationAzidation BrominationBromination Reactions involving Butyl Lithium Reactions involving Butyl Lithium CyanationCyanation Chiral chemistryChiral chemistry GriganardGriganard Sodium metal reactionsSodium metal reactions Metal hydride reductionsMetal hydride reductions Optical ResolutionOptical Resolution High Pressure ReactionsHigh Pressure Reactions HydrogenationHydrogenation High Temperature Reactions (250°C)High Temperature Reactions (250°C) High Vacuum DistillationsHigh Vacuum Distillations Low Temperature Reactions (-80°C)Low Temperature Reactions (-80°C)

1818

Formulation BusinessFormulation Business

Wanbury Limited

Our Formulation Our Formulation Business Business Founded in 1865 by Dr. George Wander in Berne, Switzerland Founded in 1865 by Dr. George Wander in Berne, Switzerland

Wander has been in the Indian market since late forties with Wander has been in the Indian market since late forties with it’s cold and nutrition products …originally a subsidiary of it’s cold and nutrition products …originally a subsidiary of SandozSandoz

Now a Wanbury division with 310 professionals, 16 brands, Now a Wanbury division with 310 professionals, 16 brands, 24 Distributors and about 1200 stockists across the country.24 Distributors and about 1200 stockists across the country.

Independent Formulation Research and Development Centre Independent Formulation Research and Development Centre at Chembur recognised by Govt. of Indiaat Chembur recognised by Govt. of India

Strong focus on Pediatrics, Gynecology and Orthopedics Strong focus on Pediatrics, Gynecology and Orthopedics

Growth through niche neutraceuticals led lifestyle segmentGrowth through niche neutraceuticals led lifestyle segment

Wanbury Limited

Brands Brands

Doctor SegmentDoctor Segment Brands Brands

PediatricsPediatrics

C-PinkCoriminic

ZevaNurture SetCal

Gemron Cemax-OCefcareOftek Ofgyl

Nock -2Adtrol

ClamistSenasof

C-PinkCoriminic

ZevaNurture SetCal

Gemron Cemax-OCefcareOftek Ofgyl

Nock -2Adtrol

ClamistSenasof

GynecologistsGynecologists

Orthopedics Orthopedics

Consulting Physicians GPs

Consulting Physicians GPs

2121

Growth StrategyGrowth Strategy

Wanbury Limited

Growth StrategyGrowth Strategy

Existing Satisfied CustomersExisting Satisfied Customers

Strong Marketing SkillsStrong Marketing Skills

In-house technical In-house technical competencecompetence

In-house Research expertiseIn-house Research expertise

Experience in managing and Experience in managing and building US FDA approved building US FDA approved plantsplants

LEVERAGE ON ….LEVERAGE ON ….

ExpansionExpansion

Contract Contract ManufacturingManufacturing

Product Product IntroductionsIntroductions

Global Global GenericsGenerics

4 Years

Life Style Life Style DivisionDivision

Improve PCPMImprove PCPM

Strategic Strategic AllianceAlliance

AcquisitionsAcquisitions

2323

ManagementManagement

Wanbury Limited

Mr. K ChandranMr. K Chandran ..ED..ED

Mr. K.R.N. MoorthyMr. K.R.N. Moorthy ..ED..ED

Mr. N. K. PuriMr. N. K. Puri ..Independent ..Independent

Dr. P. L. Tiwari Dr. P. L. Tiwari ..Independent ..Independent

Mr. A. BongirwarMr. A. Bongirwar ..Independent..Independent

Mr. S. BhattacharyaMr. S. Bhattacharya ..Nominee(EXIM)..Nominee(EXIM)

Board of Directors

Wanbury Limited

Mr. K. R. N. Moorthy is supported by Mr. K. R. N. Moorthy is supported by an advisory board: an advisory board:

– Mr. S. Balsekhar, Mr. S. Balsekhar, Ex-Chairman Roussel PharmaceuticalEx-Chairman Roussel Pharmaceutical

– Dr. Indira Parekh, Dr. Indira Parekh, Dean IIM AhmedabadDean IIM Ahmedabad

– Group DirectorsGroup Directors

Advisory Board

Wanbury Limited

Human ResourcesHuman Resources

Human Resources

R&D (API), 30Formulation Sales and Marketing ,

310

Manufacturing -On Rolls, 225

QC, QA and RA, 30

Manufacturing - On Contract, 160

Services and Corporate Office,

75

Wanbury Limited

Key Personnel

BOARD of DIRECTORSADVISORY BOARD

K R N MOORTHYED & President APIs/Formulations

Vijayan Nair GM Finance

Dr. Pulla Rao Head QA and Regulatory

S R Jagannathan Sr. VP Operations

ASHOK SHINKARDirector C F (M&A)

Dr S Samant V P Marketing

M.K. PADMANABHANNational Sales Manager

Raman IyerGM Marketing

V S AyareR&D

S Jayaram V P Legal

Dr Shankar GM R&D

Kurush Dubash Head Training

Surina Iyer DGM HR

P. GuptaCompany Sec.

Mahesh KolatkarAGM IT

Wanbury Limited

Management – Key personnel Name Designation Experience

Mr. Ashok Shinkar

Director Corporate Finance 12 years with J.M.Morgan Stanley and SSKI Corporate Finance

Mr. S. R. Jagannathan SVP - Technical 28 years with Ranbaxy, Sanmar Chemplast, Shasun Chemicals and Drugs, Matrix Laboratories

Dr Y Pulla Rao

SVP - QA and Regulatory 26 years with IDPL, SOL Pharma, Neuland Laboratories, Jubliant Organics

Dr.Rajaram S Samant VP– Marketing (Formulations)

8 Yrs with USV, Ranbaxy, Emcure

Mr. S. Jayaram

VP – Legal

37 years with Crompton Greaves, Innovation Equipment, M&M, Boots Pharma & Khandelwal Builders

Mr.M.K.Padmanabhan

National Sales Manager

22 years with Ranbaxy, Mircro Lab

Mr. Vijayan Nair

GM Finance

24 years with Concept, Lupin, Parekh Dyechem

Dr. S. Shankar

GM – R&D

17 years with Calyx, Chemspec, IPCA, E.Merck

Mr. Raman Iyer

GM – Exports (API)

22 years with Concept, Ranbaxy, Alkem, Vorin, Aarti

Mr. Kurush F. Dubash

Head of Training

32 years with Wockhardt Pharma & Pfizer Ltd

Mr. Anand Dhoka

DGM -Commercial

28 years with Maharashtra Polybutenes, EPIC, Sriman Group, Cyanides & Chemicals

Mr. Sabu Daniel

DGM – Marketing (API) 16 years with Aarti Drugs, Rajasthan Glyoxal

Mrs. Surina Iyer DGM – HR 11 Yrs with L&T, Lavasa Corporation

Mr. Pankaj B. Gupta

Company Secretary

4 years with Grasim Industries Ltd, Global Boards Ltd

Ms. Janki Desai

Marketing Manager

9 years with GlaxoSmithKline & Cipla Ltd

Mr. Mahesh Kolatkar AGM - IT 20 years with Baan Infosystem, Raymonds etc.

Wanbury Limited

HR Thrust .. Focus Areas HR Thrust .. Focus Areas

Talent Acquisition – Selection Techniques Talent Acquisition – Selection Techniques

Team Alignment & RationalizationTeam Alignment & Rationalization

Measuring Performance & Assessing Potential Measuring Performance & Assessing Potential

Compensation BenchmarkingCompensation Benchmarking

Capability Building and Leadership DevelopmentCapability Building and Leadership Development

Career Development & Succession Planning Career Development & Succession Planning

Create Think Tank ~ Innovative Practices Create Think Tank ~ Innovative Practices

Communication – Openness – Transparency - SpeedCommunication – Openness – Transparency - Speed

System Orientation System Orientation

Building Human Capital ….. For Superior & Competitive Results

Wanbury Limited

Respect for People

Innovation

Sense of Urgency

Result Focus

Leadership

Team Work

Customer Focus

Wanbury’s VALUES Wanbury’s VALUES

Wanbury Limited

We at Wanbury, want to make a company that employees are proud of and committed to, where every employee has an opportunity to contribute, learn, grow and advance on merit.

We are dedicated in improving quality of our employees by continuously providing high quality training and development.

We will continue to establish a business model, which is predictable, sustainable, growth oriented and profitable.

We will always worship exceptional and superior performance. We will continuously challenge status-quo / maintenance and simultaneously encourage and recognize stretch and growth.

We will work hard not only to satisfy but delight our customers (both internal and external).

We will strive to make Wanbury one of the preferred employers.

Mission statementMission statement

3232

Thank YouThank You